VNP 20009

Drug Profile

VNP 20009

Latest Information Update: 14 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vion Pharmaceuticals
  • Developer EPTTCO; Vion Pharmaceuticals
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 14 Oct 2002 Discontinued - Phase-I for Cancer in USA (IV-injection)
  • 14 Oct 2002 Discontinued - Phase-I for Lymphoma in England (IV)
  • 14 Oct 2002 Discontinued - Phase-I for Solid tumours in United Kingdom (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top